For the inv(16) AML subgroup, the pooled RRs of OS were 1.03 (95% CI: 0.90–1.18; P = 0.23, I2 = 25%) and 1.01 (95% CI: 0.86–1.18; P = 0.23, I2 = 25%) in the fixed- and random-effects models, respectively, suggesting no significant KIT mutation-related decrease in the OS of inv(16) AML. The gene discussed is KIT; the disease is acute myeloid leukemia.